UNLIMITED TURBO LONG - NOVO-NORDISK B | Real-time Borsa Italiana 04:07:14 2024-07-09 am EDT | ||
| 2.79 EUR | -5.42% |
|
| Current month | -7.52% | ||
| 1 month | -2.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-09 | 2.79 | -5.42% |
| 24-07-08 | 2.95 | +3.69% |
| 24-07-05 | 2.845 | +3.45% |
| 24-07-04 | 2.75 | +5.16% |
| 24-07-03 | 2.615 | -13.41% |
Real-time Borsa Italiana
Last update July 09, 2024 at 04:07 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| P1Z216 | |
| ISIN | NLBNPIT1Z216 |
| Date issued | 2024-02-07 |
| Strike | 788.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.57 € |
|---|---|
| Lowest since issue | 0.724 € |
| Spread | 0.005 € |
| Spread % | 0.18% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984.6
DKK
Average target price
952.2
DKK
Spread / Average Target
-3.30%
- Stock Market
- Certificates
- P1Z216 Certificat
